Smith & Nephew sustainability score: 53/100

·Healthcare / Pharmaceuticals·Last verified 3 October 2026
53
out of 100
Making progressPending Review+2 since last reviewMixed evidence· 8 src

Smith & Nephew scores 53/100 (Making progress) on SINK's independent climate assessment — scored from public data only, no company payment can change a number. Last verified October 2026.

That places Smith & Nephew joint 77th of 809 companies scored, and 1st of 15 in Healthcare / Pharmaceuticals.

Smith & Nephew reports genuine 63% absolute emissions cuts (Scope 1+2) and 59% Scope 3 reductions since 2021, backed by third-party verification. Energy transition is real but hampered by reliance on unbundled renewable energy certificates. Nature impact, water stewardship, and SBTi validation remain underdeveloped.

For buyers

Buy from Smith & Nephew? Check your whole supplier list.

Every supplier scored from public evidence like this, ranked, in 48 hours. No questionnaires, and your suppliers never know.

Check your suppliers →
Is this your company?

Think we've missed something? Tell us, free.

This score uses public evidence only. Challenge any question for free, or ask for a human review of evidence you haven't published.

Evidence review, £99 →
The calculation

How is Smith & Nephew's SINK score calculated?

Same ten questions for every company. No private weighting.

SINK = (0.3 × Base + 0.7 × Performance) × Scale
Industry base impact
Healthcare / Pharmaceuticals sector ceiling.
45 / 100
Performance score
Sum of the 10 rubric questions, scored 0–10 each.
61 / 100
Raw score
Weighted average before scale penalty.
(0.3 × 45) + (0.7 × 61) = 56.2
Scale penalty
Multiplier based on absolute emissions volume — physics-first.
× 0.95
Final score
Rounded. Making progress.
53 / 100
The ten questions

What is Smith & Nephew doing well, and where does it fall short?

Strongest on Carbon Footprint — Operations and Emissions Trajectory (8/10, 8/10). Weakest on Nature & Biodiversity Impact and Water Impact (3/10, 4/10).

Where the evidence comes from

What evidence is Smith & Nephew's score based on?

8 sources used in this assessment. All publicly available. Each row shows which rubric questions it informed.

[1]SEC filing
SEC Form 20-F: Smith & Nephew PLC, year ended 31 December 2024

“In 2024, the total market-based Scope 1 and Scope 2 GHG emissions footprint was 24,662 tonnes of CO2e.”

2025
Q1Q2Q3Q4Q7Q8
View →
[2]Self-reported
Smith & Nephew Annual Sustainability Report 2024

“Data independently assured by ERM CVS; more details and the full assurance report are available in the 2024 Sustainability Report on pages 46–47.”

2025
Q1Q2Q3Q4Q6Q9
View →
[3]Self-reported
Smith & Nephew Official Sustainability Page

“Smith+Nephew received an A rating in the assessment, which evaluates corporate supply chain engagement practices on climate issues.”

Ongoing
Q2Q6Q7
View →
[4]SEC filing
SEC Form 20-F: Smith & Nephew PLC, year ended 31 December 2022

“We are developing our Scope 3 emissions reduction roadmap in preparation for submitting this to the Science Based Target Initiative (SBTi) for validation.”

2023
Q8
View →
[5]SEC filing
SEC Form 20-F: Smith & Nephew PLC, year ended 31 December 2021

“we are mindful of the importance of biodiversity, particularly in some of the countries in which we operate including Costa Rica and Malaysia.”

2022
Q5
View →
[6]Public record
Good Jobs First Violation Tracker — Smith & Nephew

“environmental violation $12,500 1 — Smith & Nephew Inc. — EPA — 2025”

Ongoing
Q10
View →
[7]SEC filing
SEC Litigation Release No. 22252 — FCPA Settlement

“Smith & Nephew Inc., agreed to pay a $16.8 million fine to settle parallel criminal charges announced by the U.S. Department of Justice.”

2012
Q10
View →
[8]Self-reported
Smith & Nephew Board Committee Governance & ESG Oversight

“The 2024 Annual Report on Form 20-F was filed with the SEC earlier today.”

2026
Q9
View →

If you believe a source has been misread or a newer version exists, submit a challenge.

Smith & Nephew in context

How does Smith & Nephew compare with other healthcare / pharmaceuticals companies?

Smith & Nephew is the highest-scoring healthcare / pharmaceuticals company we've rated.

Among the 15 major healthcare / pharmaceuticals brands we've scored, Smith & Nephew sits 1st of 15.

1/15
Smith & Nephew's rank
46
Industry average
39
Industry low
53
Industry high
How this score has moved

Has Smith & Nephew's score changed?

Smith & Nephew's score has moved from 51 to 53 across 2 recorded reviews — up 2 points.

0255075100512 August 2026533 October 2026
  1. 51 → 53+23 October 2026

    Aggregator-citation sweep: broker citations replaced with the primary disclosures they mirror, re-scored through the guarded pipeline under pinned code 9196601.

  2. Scored 512 August 2026

    Initial public score 51 (publish-draft)

What's being contested

Has Smith & Nephew's score been challenged?

This score is not currently being contested.

Every challenge is published. We'd rather be corrected than wrong — that's the whole point.

No challenges submitted yet. If you have evidence that contradicts this score, you can challenge any question above — cite a public source and we'll review it.

About Smith & Nephew

Smith & Nephew is a London-headquartered medical technology manufacturer founded in 1856, employing 11,000 people globally. It designs, manufactures and distributes surgical products, wound care, orthopaedic reconstruction, trauma devices, and advanced wound bioactives across 90+ countries. Mid-cap healthcare equipment supplier with diversified geographic footprint.

Founded
—
Headquarters
United Kingdom
Employees
~17,500
Annual revenue
~$5.8B
Company website ↗
Track Smith & Nephew

We'll let you know when the score moves.

Email alerts when a rubric question is verified, a challenge is resolved, or the overall score changes.

THE SUNDAY RUNDOWN

Which companies moved this week, and why.

One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.

No spam. Unsubscribe in one click.

Nobody can pay us to change a number.